Top Markets
#1 Islamic Coin Islamic Coin +151.22%
#2 Akedo Akedo +76.34%
#3 Velvet Velvet +52.62%
#4 Glidr Glidr +51.75%
#5 DOVU DOVU +47.94%
#6 Black Phoenix Black Phoenix +33.93%
#7 Cross Cross +31.13%
#8 Cap Cap +21.55%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.55%
#10 DoubleZero DoubleZero +14.82%
Coin of the day
Islamic Coin Islamic Coin
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
Peringkat dalam Saham #39465
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Harga Saham
$0.11725176
Terakhir disinkronkan: 2025-07-14
Kapitalisasi Pasar
$481.50K
Perubahan (1 hari)
-0.20%
Perubahan (1 tahun)
0.00%
Negara
FR
Perdagangan PHAXIAM Therapeutics S.A. (PHXM)

Kategori

Healthcare
Pendapatan untuk PHAXIAM Therapeutics S.A. (PHXM)
Pendapatan pada Jun 2024 TTM: $2.30M
Menurut laporan keuangan terbaru dari PHAXIAM Therapeutics S.A., pendapatan saat ini (TTM) adalah $2.30M. Pada tahun 2022, perusahaan menghasilkan pendapatan sebesar $7.13M peningkatan dibandingkan pendapatan pada tahun 2021 yang sebesar $4.75M. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan PHAXIAM Therapeutics S.A. dari 2016 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Mengubah
2026 (TTM) $2.30M 56.82%
2023 $1.47M -79.44%
2022 $7.13M 50.00%
2021 $4.75M 4.97%
2020 $4.53M -23.61%
2019 $5.93M 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
Pendapatan untuk perusahaan serupa atau pesaing
Perusahaan Pendapatan Perbedaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 549,098.33%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 261,845.69%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B 439,752.28%
BE